Skip to content

A case-control study on the correlation between VLA-3 high and/or VLA-6 high neutrophil and prognosis in acute ischemic stroke patients

A case-control study on the correlation between VLA-3 high and/or VLA-6 high neutrophil and prognosis in acute ischemic stroke patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300068780
Enrollment
Unknown
Registered
2023-02-28
Start date
2023-03-01
Completion date
Unknown
Last updated
2023-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Interventions

mRS =2 vs. mRS <2:Nil

Sponsors

Beijing Tsinghua Changgung Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years. 2. First-time symptomatic acute ischemic stroke. 3. 12ml of peripheral blood samples are successfully retained within 24 hours after consultation (reserve pre-treatment blood samples for patients undergoing thrombolysis). 4. Admitted as inpatients with detailed clinical records.

Exclusion criteria

Exclusion criteria: 1. Patients with hemorrhagic stroke. 2. Patients undergo endovascular recanalization therapy or bridging endovascular recanalization therapy. 3. Patients have serious systemic diseases that may affect life expectancy, including cancer, cardiopulmonary or liver and kidney failure, etc. 4. Patients have infectious diseases that lead to an elevation in neutrophil count or activation. 5. Patients have diseases that cause immunosuppression or need to use immunosuppressive drugs. 6. Patients with incomplete clinical records.

Design outcomes

Primary

MeasureTime frame
mRS score of 90 days after first-time symptom onset;

Secondary

MeasureTime frame
mRS score of 30 days after first-time symptom onset;early neurological deterioration;

Countries

China

Contacts

Public ContactJian Wu

Beijing Tsinghua Changgung Hospital, Tsinghua University

wujianxuanwu@126.com+86 10 5611 8918

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026